These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27039923)

  • 1. Anticancer Drug Combinations, How Far We can Go Through?
    Lu DY; Chen EH; Wu HY; Lu TR; Xu B; Ding J
    Anticancer Agents Med Chem; 2017; 17(1):21-28. PubMed ID: 27039923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Combination in Clinical Cancer Treatments.
    Lu DY; Lu TR; Yarla NS; Wu HY; Xu B; Ding J; Zhu H
    Rev Recent Clin Trials; 2017; 12(3):202-211. PubMed ID: 28782482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics.
    Lu DY; Qu RX; Lu TR; Wu HY
    Rev Recent Clin Trials; 2017; 12(2):101-110. PubMed ID: 28190390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highlights in Resistance Mechanism Pathways for Combination Therapy.
    Delou JMA; Souza ASO; Souza LCM; Borges HL
    Cells; 2019 Aug; 8(9):. PubMed ID: 31480389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational oncology--mathematical modelling of drug regimens for precision medicine.
    Barbolosi D; Ciccolini J; Lacarelle B; Barlési F; André N
    Nat Rev Clin Oncol; 2016 Apr; 13(4):242-54. PubMed ID: 26598946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted agents: the rules of combination.
    Kwak EL; Clark JW; Chabner B
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer.
    Singh T; Neal AS; Moatamed NA; Memarzadeh S
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drosophila as a novel therapeutic discovery tool for thyroid cancer.
    Das T; Cagan R
    Thyroid; 2010 Jul; 20(7):689-95. PubMed ID: 20578898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Curcumin the Answer to Future Chemotherapy Cocktail?
    Kong WY; Ngai SC; Goh BH; Lee LH; Htar TT; Chuah LH
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging combination therapies to overcome resistance in EGFR-driven tumors.
    Ratti M; Tomasello G
    Anticancer Drugs; 2014 Feb; 25(2):127-39. PubMed ID: 24113593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting.
    Hafez N; Rugo HS; Tempero MA; Fox E; Reaman GH; Lyerly HK; Walker D; LoRusso PM
    Clin Cancer Res; 2020 Sep; 26(18):4743-4747. PubMed ID: 32571790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
    Duncan R; Vicent MJ; Greco F; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S189-99. PubMed ID: 16113096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision cancer medicine: where to target?
    Yu Q; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1161-2. PubMed ID: 26388154
    [No Abstract]   [Full Text] [Related]  

  • 16. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
    Masui K; Gini B; Wykosky J; Zanca C; Mischel PS; Furnari FB; Cavenee WK
    Carcinogenesis; 2013 Apr; 34(4):725-38. PubMed ID: 23455378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
    Jhaveri K; Modi S
    Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of anti-cancer action and pharmacology of clofarabine.
    Zhenchuk A; Lotfi K; Juliusson G; Albertioni F
    Biochem Pharmacol; 2009 Dec; 78(11):1351-9. PubMed ID: 19576186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs in refractory colorectal cancer.
    Nobili S; Galletta A; Brugia M; Tassi R; Petreni P; Landini I; Mini E
    Future Med Chem; 2015 Aug; 7(12):1491-501. PubMed ID: 26293581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Strategies for the overcoming of drug resistance].
    Saijo N
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):371-81. PubMed ID: 7880108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.